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 Abstract   
Objectives: To determine the effects of tamoxifen and hormone replacement therapy in order to assess their role 
in depressive behavior.
Material and Methods: Different protocols of hormone replacement therapies were administered to surgically 
ovariectomized rats. Intact rats were used for tamoxifen experiments. Properly assigned control groups were used 
and cognitive processes were studied on animal models of surgical menopause using the Porsolt Forced Swim Test 
and locomotor activity experiments.
Results: In the tamoxifen experiments, an interaction between treatment and days did not reach statistical 
significance, but indicated a trend in this direction [F(1,26)=3.557, p=0.071]. The number of repeated movements 
significantly decreased after the Porsolt test (F(1,44) = 8.483, P<0.006) in the hormone replacement experiments. 
In the tamoxifen experiments, the number of repeated movements significantly decreased after the Porsolt test 
(F(1,26) = 74.410, P<0.001).
Conclusions: While sequential hormone replacement is found to be protective against depression, tamoxifen 
seems to augment behavioral despair.
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Introduction
In	 the	 postmenopausal	 period	 many	 body	 systems	 are	
affected	by	reduced	estrogen	levels	and	have	a	negative	impact	






Experimental	and	clinical	 studies	provide	evidence	 for	 the	
antidepressant	and	cognitive	effects	of	estrogens	[2-7].	An	increase	
in	sensory	perception,	decreased	seizure	threshold,	reduced	acute	
phase	 inflammatory	response,	 increased	 in	cerebral	blood	flow,	
augmented	 cerebral	 blood	 glucose	 utilization,	 enhanced	 mood	
effects,	 and	 reduced	 formation	 of	 β-amyloid	 have	 been	 shown	
[8].
Selective	 estrogen	 receptor	 modulators	 (SERMs)	 are	
synthetic,	 non-hormonal	 compounds	 acting	 as	 estrogen	
agonists	on	tissues	such	as	bone	and	brain,	while	functioning	as	
estrogen	 antagonists	 on	 other	 tissues,	 including	 the	 breast	 and	
the	 uterus	 [9,	 10].	 Recent	 studies	 [11,	 12],	 as	 well	 as	 a	 study	
conducted	in	our	department	[13],	have	indicated	that	raloxifene	







The	 objective	 of	 the	 present	 study	 was	 to	 determine	 the	
effects	 of	 tamoxifen	 and	 hormone	 replacement	 therapy	 with	
different	 hormone	 regimens	 to	 assess	 their	 role	 in	 depressive	
behavior.
Material and methods








Communities	Council	Directive	 (2003/003)	 and	 guided	 by	 the	
‘International	 Guiding	 Principles	 for	 Biomedical	 Research	
Involving	Animals’	 developed	by	 the	Council	 for	 International	
Organizations	of	Medical	Sciences	(NIH).	All	the	animals	were	
handled	before	the	tests.
Surgical procedure:	 Postmenopausal	 status	 was	 achieved	
by	 bilateral	 surgical	 ovariectomy.	 Rats	 were	 anaesthetized	 by	
thiopental	 sodium	 (Pentotal;	 40mg/kg,	 intraperitoneal).	 The	
ovaries	were	exteriorized	through	small	bilateral	flank	incisions	
(1	cm	each),	 the	 junctions	between	 the	 fallopian	 tubes	and	 the	
ovaries	were	 ligated,	 the	sides	of	 the	ovaries	were	cut,	and	 the	
ovaries	were	removed.	The	horns	were	returned	to	the	abdominal	
cavity	 through	the	openings	and	 the	skin	 incisions	were	closed	
with	 sutures.	During	 the	 recovery	period	 (1	week)	 the	animals	
were	 housed	 singly	 in	 the	 cages.	 Following	 recovery	 from	 the	
surgery,	 the	 rats	 were	 kept	 under	 standard	 colony	 conditions.	
After	 21	 days	 the	 rats	 were	 randomly	 allocated	 to	 study	 and	
control	groups.	












 Streszczenie   
Cel: Określenie wpływu tamoxifenu oraz hormonalnej terapii zastępczej celem oceny ich roli w zachowaniach 
depresyjnych.
Materiał i metody: Różne protokoły hormonalnej terapii zastępczej zastosowano u szczurów poddanych 
chirurgicznemu usunięciu jajników. Tamoxifen podawano szczurom, których nie operowano. Wykorzystano 
odpowiednio dobraną grupę kontrolną. Zbadano procesy poznawcze na modelach zwierzęcych z chirurgiczną 
menopauzą przy pomocy testu Porsolt Forced Swim oraz doświadczeń aktywności ruchowej.
Wyniki: W doświadczeniach z tamoxifenem, związek pomiędzy terapią a dniami nie osiągnął statystycznej istotności, 
ale wykazał trend w tym kierunku [F(1,26)=3,557,p=0,071]. Liczba powtórzeń ruchów istotnie zmniejszyła się po 
teście Porsolta [F(1,44)=8,483,p<0,006] w doświadczeniach z hormonalną terapią zastępczą. W grupie leczonej 
tamoxifenem liczba powtórzeń ruchów istotnie zmniejszyła się po teście Porsolta [F(1,26)=74,410, p<0,001].
Wnioski: Wydaje się, że sekwencyjna terapia hormonalna pełni ochronną funkcję przed depresją, natomiast 
tamoxifen nasila zachowania depresyjne.
 Słowa kluczowe:  tamoxifen / hormonalna terapia zastępcza / depresja / menopauza / 
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swim.	The	 rats	were	 placed	 individually	 in	 a	 cylinder	 (height,	





















Locomotor activity experiments.	 The	 locomotor	 activity	
of	 each	 group	 of	 animals	 was	 tested	 in	 30x30x30	 transparent	
plexiglass	 cages.	 The	 cages	 were	 comprised	 of	 infrared	 light	





the	 same	 light	 source	more	 than	once	 by	moving	on	 the	 same	
side	of	 the	cage	as	repeated	movements.	Repeated	movements,	
such	 as	 rearing,	 grooming,	 and	 extremity	movements,	 indicate	







of	 freedom	 (df)	 values	 exceeding	 unity	 in	 the	 numerator	were	
set	 to	 unity	 in	 a	 conservative	 Geisser-Greenhouse	 correction	
procedure;	the	level	of	rejecting	the	null	hypothesis	was	0.05.
Result
Porsolt FST.	 In	 hormone	 replacement	 experiments,	





groups,	 suggesting	 estrogen	 replacement	 to	 be	 effective	 in	
reducing	freeze	duration.	In	swim	duration,	only	days	emerged	
as	a	significant	factor	[F(4,63)	=	5.487,	p	=	0.022],	but	no	other	




Figure 1. Freeze duration results of the Porsolt Forced Swim Test  
Cont: Intact control animals TAM: Tamoxifen OVX-V: Ovariectomy and vehicle, 
OVX-E: Ovariectomy and estrogen, OVX-EP: Ovariectomy and combined 
estrogen and progesterone, OVX-EintP: Ovariectomy and intermittent (sequential) 
progesterone. Different from OVX-V or Control  (Day 2): *p<0.05
Figure 2. Struggle duration results of the Porsolt Forced Swim Test  
Cont: Intact control animals TAM: Tamoxifen OVX-V: Ovariectomy and vehicle, 
OVX-E: Ovariectomy and estrogen, OVX-EP: Ovariectomy and combined 
estrogen and progesterone, OVX-EintP: Ovariectomy and intermittent (sequential) 
progesterone. Different from OVX-V (Day 2): *p<0.05. Different from control (Day 1): 
†p<0.05.
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as	 the	 increase	 in	 the	 freeze	duration	was	much	higher	on	day	
2	compared	to	intact	rats.	Along	the	same	lines,	on	the	2nd	day	
there	 was	 a	 trend	 in	 the	 tamoxifen-treated	 group	 for	 a	 higher	






Locomotor activity experiments.	 The	 number	 of	 repeated	
movements	significantly	decreased	after	the	Porsolt	FST	(F(1,44)	
=	 8.483,	 P<0.006)	 in	 the	 hormone	 replacement	 experiments.	
Hormone	replacement	also	emerged	as	a	significant	factor	(F(1,44)	








The	 combined	 estrogen-progesterone	 replacement	 group	 had	
a	 significantly	 lower	 number	 of	 repeated	 movements	 than	 the	
vehicle	and	estrogen-treated	ovariectomized	groups	(p<0.05).		
In	 the	 tamoxifen	 experiments,	 the	 number	 of	 repeated	
movements	significantly	decreased	after	the	Porsolt	FST	(F(1,26)	
=	 74.410,	 P<0.001).	 Tamoxifen	 treatment	 also	 emerged	 as	
a	 significant	 factor	 (F(1,26)	=	5.969,	P<0.022).	 	On	day	1,	 the	
tamoxifen-treated	group	had	a	higher	score	than	the	control	one	
based	on	the	Student’s	t-test	(p	=	0,013)
































evaluated	 the	 effects	 of	 hormones	 on	 mood	 in	 peri-and	 post-
menopausal	women;	overall	effect	sizes	of	0.68	for	estrogen	and	
progesterone	 and	0.69	 for	 unopposed	 estrogen	 are	 shown.	The	









for	 5	 years,	 no	 difference	 existed	 between	 the	 tamoxifen	 and	
placebo	groups	with	respect	to	depression	and	overall	quality	of	
life	 [19].	 In	 a	 recent	 study	 of	 our	 laboratories	we	 investigated	
the	 effects	 of	 raloxifene	 on	 cognition	 and	 depression	 in	 rat	
experimental	 models.	 Raloxifene	 decreased	 immobilization	
(p<0.001)	 and	 increased	 struggling	 (p<0.001)	 in	 the	 Porsolt	
FST	 suggesting	 the	 prevention	 of	 despair.	 Raloxifene,	 as	
a	 SERM,	 acts	 as	 an	 antidepressant	 in	 ovariectomized	 rats	 and	
has	a	positive	 impact	on	memory	despite	 the	negligible	effects	




Although	 the	number	of	 repeated	movements	 significantly	
decreased	after	the	Porsolt	FST	in	locomotor	activity	experiments,	
the	tamoxifen	group	had	a	significantly	higher	number	of	repeated	




of	 cage	 crosses	 significantly	 decreased	 after	 the	 Porsolt	 FST,	
with	the	tamoxifen	group	showing	a	significantly	higher	number	
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